From the Research
Avian Influenza A (H5N1) Virus Vaccine
- There are multiple vaccines in development for humans to protect against avian influenza, specifically the H5N1 virus 1.
- A cell-based vaccine called Audenz has been approved by the FDA for people aged 6 months and older who are at higher risk of exposure to the H5N1 virus 1.
- Effective vaccines against the highly pathogenic influenza A/H5N1 virus are being developed worldwide, including adjuvanted, inactivated, whole-virion influenza vaccines 2.
- mRNA vaccine candidates targeting panzootic influenza A(H5) clade 2.3.4.4b viruses have shown promise in protecting ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virus 3.
- Prepandemic candidate vaccines are being developed, including a live attenuated H5N1 vaccine lacking NS1, which has shown safety and immunogenicity in healthy adult participants 4.
Types of Vaccines
- Inactivated influenza vaccines are the most frequently developed for immunization against the highly pathogenic avian H5N1 influenza virus 4.
- Live attenuated H5N1 vaccines, such as delNS1-H5N1, are being investigated for their safety and immunogenicity 4.
- mRNA vaccines are being developed as a potential vaccine platform for future influenza pandemics 3.
- Cell-based vaccines, such as Audenz, are being used to protect against avian influenza 1.
Vaccine Development and Approval
- The development of H5N1 vaccines involves overcoming various obstacles, including quality control and formulation stability tests 2.
- Vaccine quality is confirmed by quality control, stability, and pre-clinical tests before clinical trials are initiated 2.
- The FDA has approved a cell-based vaccine called Audenz for people aged 6 months and older who are at higher risk of exposure to the H5N1 virus 1.
- The Ministry of Health and Labor Welfare of Japan has approved an adjuvanted, inactivated, whole-virion influenza vaccine as a mock-up, pre-pandemic vaccine formulation 2.